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  ABSTRACT 
  Viperid snakes of the genus   Atropoides   are distributed in Mexico and Central America and, owing to their 
size and venom yield, are capable of provoking severe envenomings in humans. This study evaluated, using an 
‘antivenomics’ approach, the ability of a polyspeciﬁ  c (polyvalent) antivenom manufactured in Costa Rica to 
recognize the proteins of   Atropoides mexicanus   and   A. picadoi   venoms, which are not included in the immu-
nization mixture. In addition, the neutralization of lethal, hemorrhagic, myotoxic, coagulant, proteinase and 
phospholipase A  2   (PLA 2  ) activities of these venoms by the antivenom was assessed. The antivenom was highly-
effective in immunodepleting many venom components, particularly high molecular mass P-III metallopro-
teinases (SVMPs), L-amino acid oxidases, and some serine proteinases and P-I SVMPs. In contrast, PLA  2 s, 
certain serine proteinases and P-I SVMPs, and a C type lectin-like protein were only partially immunodepleted, 
and two PLA  2   molecules were not depleted at all. The antivenom was able to neutralize all toxic and enzymatic 
activities tested, although neutralization of lethality by   A. nummifer   venom was achieved when a challenge dose 
of 3 LD  50  s of venom was used, but was iffective when 4 LD  50  s were used. These results, and previously obtained 
evidence on the immunoreactivity of this antivenom towards homologous and heterologous venoms, revealed 
the low immunogenicity of a number of venom components (PLA  2  s, CRISPs, P-I SVMPs, and some serine 
proteinases), underscoring the need to search for innovative immunization protocols to improve the immune 
response to these antigens.       
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 INTRODUCTION 
  Animal-derived antivenoms constitute the cornerstone in the 
treatment of envenomings by snakebites worldwide (  WHO, 
2010  ). In contrast to other antibody-based immunotherapeu-
tics, such as various antitoxins and rabies immunoglobu-
lin, the antigens (snake venoms) used for the preparation 
of snake antivenoms exhibit a large intra- and inter-species 
variability (  Chippaux et al, 1991  ;   Alape-Girón et al, 2008  ; 
  Calvete et al, 2010b  ). Consequently, the selection of the 
venoms to be used in the immunizing mixtures to raise snake 
antivenoms is a key issue in the design of these immunobio-
logicals (  Gutiérrez et al, 2009a  ;   WHO, 2010  ). Antivenoms 
can be either monospeciﬁ  c, if venom of only one species 
is used for immunization, or polyspeciﬁ   c, when animals 
are immunized with venoms from two or more species 9
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provides a comprehensive view of the cross-reactivity and 
neutralization spectrum of antivenoms against homologous 
and heterologous venoms. In turn, this information can be 
used for a more rigorous design of immunizing mixtures for 
the manufacture of more effective antivenoms. 
  The venomes of two species of Atropoides snakes,   
A. nummifer   ( mexicanus  ) and   A. picadoi  , from Costa Rica 
have been recently reported (  Angulo et al, 2008  ). Despite 
the close phylogenetic kinship of these two species, their 
venoms comprise rather dissimilar proteomes, with phos-
pholipases A  2   (PLA 2  s) being the major toxins present in   
A. mexicanus   venom, whereas Zn  2+ -dependent  metallopro-
teinases (SVMPs) predominate in  A. picadoi  venom ( Angulo 
et al, 2008  ). Such proteomic proﬁ  les are consistent with the 
pathophysiological alterations induced by   A. mexicanus  
and   A. picadoi   venoms in mice, as the former induces 
prominent PLA  2  -mediated myonecrosis while the latter 
causes SVMP-mediated hemorrhage, being the venom 
with the highest hemorrhagic potential among Costa Rican 
viperids (  Gutiérrez et al, 1985  ). The present work is aimed 
at describing a detailed antivenomic assessment of the 
immunoreactivity against the venoms of   A. mexicanus   and 
  A. picadoi   of the polyspeciﬁ  c antivenom used in Central 
America. In addition, the neutralization of the most relevant 
toxic and enzymatic activities of  A. mexicanus  and  A. picadoi  
venoms by the antivenom was also investigated. The results 
evidenced a conspicuous pattern of cross-reactivity and par-
aspeciﬁ  c protection of the antivenom, but also identiﬁ  ed a 
number of venom components against which the antivenom 
has a weak antibody repertoire, thus providing useful infor-
mation for the improvement of this immunotherapeutic.     
 MATERIALS AND  METHODS 
  Venoms  and  antivenom 
  Venoms were obtained from at least 20 adult specimens of 
each species collected in Costa Rica and kept at the ser-
pentarium of Instituto Clodomiro Picado (ICP). Venoms 
were freeze-dried immediately after collection, and stored 
at -20ºC. Polyspeciﬁ  c (polyvalent, Crotalinae) antivenom 
(Batch 420, expiry date October 1  st  , 2010) from ICP was 
used. This antivenom is routinely prepared at ICP from the 
plasma of horses immunized with a mixture of the venoms 
of   Bothrops asper ,   Crotalus simus   and   Lachesis stenophrys  
(  Angulo et al, 1997  ), and consists of immunoglobulins puri-
ﬁ  ed by caprylic acid precipitation (  Rojas et al, 1994  ). A con-
trol preparation of normal equine IgG was prepared by an 
identical fractionation of the plasma of horses which had not 
been immunized with snake venoms.     
  Antivenomics: Immunodepletion of venom proteins by 
the ICP polyvalent antivenom 
  We have coined the term “antivenomics” for the proteomic 
characterization of venom proteins bearing epitopes rec-
ognized by an antivenom (  Lomonte et al, 2008  ;   Calvete 
et al, 2009a   and   2009b  ;   Gutiérrez et al, 2009a  ). Brieﬂ  y, 
two milligrams of whole venom were dissolved in 70µl of 
20mM phosphate buffer, pH 7.0, and mixed with 8mg of 
polyvalent antivenom IgGs overnight at room temperature 
(∼22ºC). IgG concentration was determined spectrophoto-
metrically at 280nm using an extinction coefﬁ  cient (ε) of 
1.4 for a 1mg/ml protein concentration determined in a 1cm 
(  Theakston et al, 2003  ;   WHO, 2010  ). In either case, the gen-
erated antibodies recognize not only proteins present in the 
homologous venoms, but also antigenically-related proteins 
present in heterologous venoms of phylogenetically-related 
species. Such paraspeciﬁ  city may in turn result in effective 
neutralization of venoms not included in the immunizing 
mixture, as has been shown in the case of   Bothrops   anti-
venoms in Latin America ( Segura et al, 2010 ). However, there 
are also situations in which antivenoms fail to neutralize ven-
oms of closely related species, as has been documented for 
neotropical rattlesnakes (  Saravia et al, 2002  ;   Calvete et al, 
2010b  ). Therefore, the detailed analysis of the paraspeciﬁ  c 
neutralization and immunoreactivity of antivenoms against 
venoms of medically-relevant species is a necessary task for 
establishing their preclinical spectrum of efﬁ  cacy. 
  The family Viperidae comprises 23 snake species in Cen-
tral America (  Campbell and Lamar, 2004  ), some of which 
are responsible for the vast majority of snakebites in this 
region (  Gutiérrez, 2009  ). These species are classiﬁ  ed within 
the genera   Agkistrodon, Atropoides Bothriechis, Bothrops, 
Cerrophidion, Crotalus, Lachesis   and   Porthidium   ( Campbell 
and Lamar, 2004  ). The genus   Atropoides   includes a number 
of thick-bodied species, known as jumping vipers, distrib-
uted in Mexico and Central America (  Campbell and Lamar, 
2004  ). Although very little information is available regard-
ing the incidence of snakebites caused by these species to 
humans, it is likely that they inﬂ  ict a number of accidents 
due to their broad distribution and relative abundance. In 
addition, the similarity of clinical symptoms with those 
caused by other pitvipers, such as   Bothrops asper ,  makes  the 
identiﬁ  cation of Atropoides bites rather difﬁ  cult. Despite the 
lack of epidemiological records on bites by these species, 
their size and relatively high venom yield (  Bolaños, 1972  ) 
suggests that they may be able to provoke signiﬁ  cant enven-
omings in humans. 
 A  polyspeciﬁ  c antivenom, prepared by immunizing horses 
with the venoms of   Bothrops asper, Crotalus simus   and 
  Lachesis stenophrys  , is widely used in Central America 
for the treatment of envenomations caused by species of 
the family Viperidae (  Angulo et al, 1997  ;   Gutiérrez, 2009  ). 
Early on after the development of this antivenom, its ability 
to neutralize the lethal effect of viperid venoms from Costa 
Rica, including those of   Atropoides   species, was demon-
strated (  Bolaños, 1971  ). Further studies evaluated the neu-
tralization of proteolytic, hemorrhagic, indirect hemolytic, 
edema-forming, coagulant and deﬁ   brinating activities of 
Central American snake venoms by this antivenom, includ-
ing the venoms of   Atropoides nummifer   ( mexicanus )  and 
  A. picadoi   (  Gutiérrez et al  ,   1985  ,   1986  ;   Rojas et al, 1987  , 
  2001  ;   Gené et al, 1989  ;   Valiente et al, 1992  ). Recently, pro-
teomic analytical tools have been adapted for the analysis 
of the immunoreactivity of antivenoms against venoms, a 
ﬁ  eld of study coined ‘antivenomics’ (  Lomonte et al, 2008  ; 
  Gutiérrez et al, 2009a  ;   Calvete et al, 2009a  ;   Calvete, 2010  ). 
Once the proteomic proﬁ   le of a particular venom (the 
‘venome’) is deciphered, then the immunoreactivity of 
antivenoms against the different venom components can 
be investigated, thus allowing a detailed assessment of the 
immune recognition scope of antivenoms. This information, 
together with the analysis of the neutralizing ability against 
speciﬁ   c toxicological and enzymatic effects of venoms, 10
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estimated as the amount of venom inducing a hemorrhagic 
halo of 10mm in the skin 2hr after injection. Myotoxicity 
was determined in mice (18-20gm) injected intramuscu-
larly, in the right gastrocnemius, with solutions of varying 
venom concentration (  Instituto Clodomiro Picado, 2008  ). 
Three hours after injection, mice were bled and the plasma 
creatine kinase (CK; E.C. 2.7.3.2) activity was determined 
by means of a kinetic assay (CK-Nac, Biocon Diagnostik, 
Germany). The Minimum Myotoxic Dose (MMD) was 
deﬁ  ned as the amount of venom that induced an increment 
in plasma CK activity corresponding to 4 times the value in 
control mice injected with PBS alone. Coagulant activity was 
determined in human citrated plasma (  Theakston and Reid, 
1983  ;   Gené et al, 1989  ). The Minimum Coagulant Dose 
(MCD) corresponds to the amount of venom that induces 
clotting of plasma in 60sec. Proteolytic activity was deter-
mined using azocasein as substrate (  Wang et al, 2004  ), as 
modiﬁ  ed by   Gutiérrez et al (2008)  . One unit of proteolytic 
activity corresponds to the amount of venom that induces a 
change in absorbance at 450nm of 0.2. PLA  2   activity was 
determined titrimetrically using egg yolk phospholipids as 
substrate (  Dole, 1956  ;   Gutiérrez et al, 1986  ). Activity was 
expressed as µEq fatty acid released per mg protein per min. 
All experiments involving the use of animals were approved 
by the Institutional Committee for the Care and Use of Lab-
oratory Animals (CICUA) of Universidad de Costa Rica. 
  Neutralization of venom activities by the polyvalent 
antivenom was assessed by using a previously described 
protocol based on the incubation of a ﬁ  xed dose of venom 
(‘challenge dose’) with various dilutions of antivenom, 
for 30min at 37ºC, in order to achieve various ratios of 
µl antivenom/mg venom (  Gutiérrez et al, 1990  ;   Instituto 
Clodomiro Picado, 2008  ). Then, aliquots of the mixtures, 
containing a challenge dose of venom, were tested in the cor-
responding experimental systems described above. Controls 
included venom solutions incubated without antivenom. 
The challenge doses of venom used were; lethality, 3 or 
4 LD  50  ; hemorrhagic activity, 10 or 5 MHD; myotoxic activ-
ity, 3 MMD in the case of  A. picadoi  and 5 MMD in the case of  
A. nummifer  ; coagulant activity, 3 MCDs; proteolytic activ-
ity, 10µg for both venoms; and PLA  2   activity, 80µg venom 
for   A. nummifer   and 40µg for   A. picadoi.   The  challenge 
doses for proteolytic and PLA  2   activities were selected from 
dose-response curves and corresponded to doses exert-
ing submaximal activity. Neutralization was expressed as 
Effective Dose 50% (ED  50  ), corresponding to the ratio µl 
antivenom/mg venom, which reduced by 50% the effect 
induced by the venom (  Gutiérrez et al, 1990  ). In the case 
of coagulant activity, neutralization was expressed as Effec-
tive Dose (ED), corresponding to the ratio µl antivenom/mg 
venom in which the clotting time of plasma was prolonged 
three times when compared with the clotting time of plasma 
incubated with venom alone. 
    RESULTS  
 Antivenomics 
    Figures 1   and   2  , and   Table 1   present the results of the 
immuno  depletion of venom proteins by the antivenom. 
The antivenom completely immunodepleted various pro-
teins of   A. mexicanus   venom (C-toxins), immunodepleted 
60-70% of the major PLA  2  s 21 and 22, and 75-80% of 
light path length cuvette (  Fasman, 1992  ). Thereafter, the 
reaction mixture was incubated for 1hr at 37ºC with 400µl 
of Protein G-Sepharose (nominal binding capacity of 20mg 
IgG/ml) (GE-Healthcare) in 20mM phosphate buffer, pH 
7.0. Protein G-bound immunocomplexes were sedimented 
at 3,000rpm for 10min in an Eppendorf microcentrifuge, 
and the supernatant was submitted to reverse-phase HPLC 
separation using an ETTAN  TM   LC HPLC system (Amer-
sham Biosciences) and a Lichrosphere RP100 C  18   column 
(250x4mm, 5µm particle size) developed at 1ml/min with 
a linear gradient of 0.1% (w/v) TFA in water (solution A) 
and acetonitrile (solution B) (5%B for 10min, followed by 
5-15%B over 20min, 15-45%B over 120min, and 45-70%B 
over 20min) (  Angulo et al, 2008  ). Protein detection was at 
215nm and peaks were collected manually and dried in a 
Speed-Vac (Savant). HPLC-fractions were assigned to pre-
viously characterized toxins (  Angulo et al, 2008  ) by their 
HPLC elution proﬁ   le, N-terminal sequencing (using a 
Procise instrument, Applied Biosystems, Foster City, CA, 
USA) and SDS-PAGE. Control samples were subjected to 
the same procedure except that control equine IgGs, instead 
of antivenom IgGs, were included in the reaction mixture. 
Quantitation of immunodepletion was assessed by compar-
ing the peak areas of control and treated samples. Depend-
ing on the extent of immunodepletion, venom proteins 
were categorized as: C-toxins, corresponding to comple-
tely immunodepleted proteins; P-toxins, corresponding to 
partially immunodepleted proteins; and N-toxins, non-
immunodepleted proteins (  Calvete et al, 2009b  ).     
  Antivenomics: Immunoblot analysis 
  The presence of polyvalent antivenom antibodies direc-
ted against antigenic determinants of   A. mexicanus   and  
A. picadoi   venom proteins was also investigated by Western 
Blot analysis. To this end, the reverse-phase HPLC chro-
matographic fractions were separated by SDS-PAGE (15%, 
w/v, polyacrylamide concentration) under non-reducing 
conditions, followed by electrotransfer to nitrocellulose 
membranes (  Towbin et al, 1979  ) using a Bio-Rad minitrans-
fer cell operated at 150mA during 90min. To assess trans-
fer efﬁ  ciency, nitrocellulose membranes were visualized by 
reversible Ponceau-S Red staining. Then, the membranes 
were destained by exhaustive washing with distilled water, 
and incubated in 2% (w/v) bovine serum albumin in phos-
phate-buffered saline solution (PBS; 0.12M NaCl, 0.04M 
sodium phosphate, pH 7.2) for 30min at room temperature 
to block non-speciﬁ  c binding sites, followed by incubation 
for 90min with 1:3,000 dilution (in PBS) of antivenom or 
control equine IgGs. After washing four times with PBS 
containing 0.2% (w/v) albumin and 0.05% (v/v) Tween-20, 
the membranes were incubated for 90min with anti-
horse IgG-alkaline phosphatase conjugate (Sigma) diluted 
1:6,000. Finally, the membranes were washed ﬁ  ve times as 
above, and color development was performed by adding 
BCIP/NBT (Chemicon) substrate.     
  Neutralization of toxic and enzymatic activities 
  The toxic and enzymatic activities of the venoms were 
assessed using previously described protocols. Brieﬂ  y, 
lethality was determined by intraperitoneal injection in 
CD-1 mice (16-18gm) (  Bolaños, 1972  ). Hemorrhage was 
assessed by the intradermal test in mice (  Gutiérrez et al, 
1985  ). The Minimmum Hemorrhagic Dose (MHD) was 11
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of   A. picadoi   that were not recognized by immunoblot were 
proteins 16 (PLA  2  ), 17 (CRISP), 18 (PLA  2  ), a P-I SVMP 
present in fractions 25, 26 and 28, and a C type lectin-like 
protein eluted in fraction 30 (  Figure 3   and   Table 1  ). In this 
venom, a number of proteins that were immunodepleted by 
the antivenom failed to be recognized by immunoblotting 
(  Table 1  ). On the other hand, PLA  2   15 and serine proteinase 
24 of   A. picadoi   venom were not immunodepleted, but were 
recognized by antivenom IgGs in western blot (  Table 1  ). 
    Neutralization of toxic and enzymatic activities 
    Table 2   displays the toxic and enzymatic activities of the 
venoms of   A. mexicanus   and   A. picadoi  . In the case of 
proteolytic activity on azocasein, it largely depends on the 
action of SVMPs, since incubation of venoms with 20 mM 
EDTA impaired by > 95% the activity of both venoms. 
On the basis of these activities, the challenge doses described 
in the Materials and Methods section were selected. The 
serine proteinases 26, 27, 28, 31 and 32 (P-toxins), and 
did not reduce the peak of PLA  2   23 (N-toxin) (  Figure 1   
and   Table 1  ). On the other hand, most proteins were 
quantitatively immunodepleted from the venom of  A. picadoi  
by the antivenom (  Figure 2   and   Table 1  ), thus corresponding 
to C-toxins. However, proteins 24 (a serine proteinase) and 
26 (a P-I SVMP) were only partially (∼40%) depleted from 
the venom, thus corresponding to P-toxins (  Table 1  ). Nota-
bly, PLA  2   15 was not immunoprecipitated at all (N-toxin). 
Immunoblot analysis was in line with most of the results 
obtained by the immunodepletion approach (  Figure 3  ). In 
the case of   A. mexicanus   venom, N- and P-toxins were also 
poorly recognized by Western blotting, with the exception 
of fractions 26 and 27 (serine proteinases). A further dis-
crepancy between immunoblotting and immunodepletion 
in   A. mexicanus   venom was on protein 24 (a cysteine-rich 
secretory protein, CRISP), which was not recognized by 
the antivenom in Western blot but was partially immunode-
pleted in the antivenomic assay. Proteins from the venom 
   Figure 1.      Reverse-phase  HPLC 
separation of proteins from control 
(  A  ) and polyvalent antivenom-
immunodepleted (  B )   Atropoides 
mexicanus   venom. Protein number-
ing and identity correspond to those 
in   Table 1   of   Angulo et al (2008)  . 
Letters correspond to fractions con-
taining IgG molecules. The inserts 
show a photo of an adult   A. picadoi  
specimen and a SDS-PAGE analysis 
of the β-mercaptoethanol-reduced 
fractions isolated by reverse-phase 
HPLC. Venom proteins are labeled 
with asterisks.     12
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lethal activity of venoms in mice (  WHO, 1981  ). Although 
the mouse lethality test still remains as the gold standard for 
antivenom potency estimation (  WHO, 2010  ), the biochemi-
cal and toxicological complexity of snake venoms urges 
a more comprehensive analysis of antivenom preclinical 
efﬁ  cacy. A relevant step forward in this area was the intro-
duction of neutralization tests based on speciﬁ  c toxic and 
enzymatic venom activities besides lethality (  Theakston, 
1986  ;   Gutiérrez et al, 1996  ;   Instituto Clodomiro Picado, 
2008  ). In the case of viperid snake venoms, the neutraliza-
tion of hemorrhagic, coagulant, deﬁ  brinogenating and myo-
toxic activities are of particular relevance. Recently, a novel 
approach in the assessment of antivenom immunoreactiv-
ity, termed ‘antivenomics’, has been developed (  Lomonte 
et al, 2008  ;   Gutiérrez et al, 2009a  ;   Calvete et al, 2009a  ). The 
antivenomic approach is based on a proteomic methodologi-
cal platform, which permits the identiﬁ  cation of all proteins 
present in venoms, allowing therefore the analysis of the 
immunoreactivity of an antivenom against each individual 
component in a venom. Immunoblotting techniques have 
polyvalent antivenom was effective in the neutralization 
of the toxic and enzymatic activities of the two   Atropoides  
venoms (  Table 3  ). Concerning the lethal activity of   A. mexi-
canus   venom, the antivenom failed to neutralize this effect 
when a challenge dose of 4 LD  50  s was used. However, the 
antivenom neutralized lethality when the challenge dose was 
3 LD  50  s. In contrast, the lethal activity of   A. picadoi   venom 
was readily neutralized by the antivenom even when using a 
challenge dose of 4 LD  50  s (  Table 3  ). Neutralization of hem-
orrhagic and PLA  2   activities required, respectively, the least 
and the highest volume of antivenom (  Table 3  ). For com-
parative purposes, the neutralizing ability of this antivenom 
against the toxic and enzymatic effects of   Bothrops asper  
venom, which is used in the immunizing mixture for the 
preparation of this antivenom, is also shown in   Table 3  .
     DISCUSSION 
  Preclinical assessment of the neutralizing ability of antiven-
oms has been traditionally based on the neutralization of the 
   Figure 2.      Reverse-phase  HPLC 
separation of proteins from control 
(  A  ) and polyvalent antivenom-
immunodepleted (  B )   Atropoides 
picadoi   venom. Protein numbering 
and identity corresponds to those 
in   Table 2   of   Angulo et al (2008)  . 
Letters correspond to fractions 
containing IgG molecules. The 
insert shows a photo of an adult 
  A. mexicanus   specimen 
and a SDS-PAGE of the 
β-mercaptoethanol-reduced 
fractions isolated by reverse-phase 
HPLC. Venom proteins are labeled 
with asterisks.     13
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proteinase, a P-I SVMP and a C-type lectin-like protein. 
There were two PLA  2  s – one in each venom – which 
were not recognized by the antivenom, being therefore 
N-toxins. The toxic proﬁ   le of these poorly recognized 
proteins remains unknown. Our ﬁ  ndings resemble previ-
ous results obtained with the venoms of   Bothrops asper  
(  Gutiérrez et al, 2010  ),   B. caribbaeus   and   B. lanceolatus  
(  Gutiérrez et al, 2008  ),   Bothriechis lateralis   and   B. schlegelii  
(  Lomonte et al, 2008  ). In these cases, high molecular 
mass venom proteins, such as P-III SVMPs and L- amino 
acid oxidases, were completely immunodepleted by the 
antivenom (C-toxins), whereas proteins of lower molecu-
lar mass, especially disintegrins, CRISPs and PLA  2 s  were 
immunodepleted only to a partial extent (P-toxins) or, in 
some cases, not depleted at all (N-toxins). Other compo-
nents of intermediate molecular mass, such as serine pro-
teinases, P-I SVMPs and C-type lectin-like proteins showed 
an intermediate pattern of immunodepletion. The fact that a 
clear relationship exists between molecular mass of venom 
proteins and their immunorecognition by antivenom IgGs 
regardless of their relative abundance in the venoms is not 
surprising, since the surface area accessible to the immune 
system is directly proportional to the molecular mass of 
the protein. Hence, the contact area of antigen and anti-
body varies between 600 and 1200 A  2   and involves about 
14-21 surface-exposed residues (  Padlan et al, 1989  ), and 
thus a small protein binds simultaneously less IgG mol-
ecules than a higher molecular mass protein. Interestingly, 
the low immunoreactivity of the polyvalent antivenom 
against a number of   Atropoides   venom toxins appears not 
to depend on the fact that these venoms were not included 
in the immunizing mixture, since a highly similar pattern 
of immunodepletion was observed against the venom of 
  B. asper   (  Gutiérrez et al, 2010  ), which is included in the 
venom mixture used in immunization (  Angulo et al, 1997  ). 
been also used for identifying venom proteins recognized by 
antivenom antibodies (  Lomonte et al, 2008  ;   Correa-Netto 
et al, 2010  ). The combination of immunodepletion, immu-
noblotting, and neutralization approaches allows a detailed 
evaluation of the preclinical efﬁ  cacy of antivenoms. Here 
we use this integrated methodology to uncover the paraspe-
ciﬁ   c reactivity and neutralization ability of a polyvalent 
antivenom against the venoms of two species of   Atropoides  
from Central America. 
 A  modiﬁ   cation of the original antivenomics protocol 
was introduced for this work. Instead of precipitating 
venom-antivenom complexes by the addition of anti-horse 
IgG, as originally described by   Lomonte et al (2008)  , the 
immune complexes were removed by adsorption to protein 
G-Sepharose beads, which bind horse IgG Fc domains, 
thereby allowing their depletion from the reaction mix-
ture by centrifugation. This modiﬁ  cation greatly reduces 
the concentration of free anti-horse IgG molecules in the 
supernatant, thus simplifying the reverse-phase chroma-
tographic separation. As in previous antivenomic studies 
(  Lomonte et al, 2008  ;   Gutiérrez et al, 2008  ;   2010  ), this 
approach was combined with western blot analysis of 
antivenom reactivity. In general, immunoprecipitation and 
immunoblotting analyses had a good correlation, with some 
exceptions. Such discrepancies may be based on the fact that 
immunoblotting is performed on denatured proteins, which 
may affect some conformational epitopes in venom compo-
nents. The antivenom recognized most of the proteins in the 
two Atropoides venoms by both antivenomic immunode-
pletion and immunoblotting. However, a number of toxins 
were immunodepleted only to a partial extent. In the case of   
A. mexicanus   venom, P-toxins included PLA  2 s,  CRISP, 
and various serine proteinases. Similarly, the   A. pica-
doi   venom’s P-toxins comprised PLA  2  s, CRISP, a serine 
Species Fractions Molecular mass (Da) Techniquea Protein  Family
A. mexicanus
21 13,751 WB and IP PLA2 (Myotoxin I)
22 13,792 WB and IP PLA2 (Myotoxin II)
24 24,744 WB CRISP
26 30,000 IP Serine proteinase
27
27
26,000
33,000
IP
IP
Serine proteinase
Serine proteinase
28 26,000 WB and IP Serine proteinase
31 34,000 WB and IP Serine proteinase
32 34,000 WB and IP Serine proteinase
A. picadoi
15 13,897.6 IP PLA2
16 13,806.6 WB PLA2
17 24,787.1 WB CRISP
18 13,790.6 WB PLA2
24 28,000 IP Serine proteinase
25 22,900 WB P-I SVMP
26 22,900 WB and IP P-I SVMP
28 22,900 WB P-I SVMP
30 28,000 WB C type lectin-like
Table 1.  Proteins from the venoms of A. mexicanus and A. picadoi that were only partially immunodepleted or not recognized by 
immunoblotting with polyvalent antivenom. Numbering of fractions corresponds to those of Figures 1 and 2.
aTechnique by which immunoreactivity was assessed: Western Blot (WB) or immunoprecipitation (IP).14
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   Figure 3.      Antivenomic  proﬁ  le of   A. mexicanus   ( A  ) and   A. picadoi   ( B  ) snake venoms by western blot analysis. Venom 
fractions isolated by HPLC were then separated by SDS-PAGE under non-reducing conditions, and transferred to 
nitrocellulose membranes. Ponceau-S Red reversible staining of transferred RP-HPLC fractions is shown at left and 
western blot of the fractions is shown at right. Lane numbers correspond to peaks in HPLC chromatography, and migra-
tion of molecular mass markers is depicted to the left. Circles are used to highlight protein bands not recognized by the 
polyvalent antivenom. Some bands not recognized by the antivenom were not included in   Table 1   because their identity 
has not been determined in proteomic analysis.     15
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there is a signiﬁ  cant antigenic similarity between the main 
toxins in   B. asper   and   Atropoides   venoms, and that the low 
immunoreactivity against some venom components in 
  Atropoides   is not due to the heterologous nature of these 
venoms but, instead, to the low immunogenicity of some 
venom components,   i.e. ,  PLA 2  s, CRISPs, and some P-I 
SVMPs and serine proteinases. 
  The proteomic differences between the venoms of 
  A. mexicanus   and   A. picadoi   have evident implications in 
the neutralization by antivenom. P-III SVMPs comprise 
56% of the venom of   A. picadoi   (  Angulo et al, 2008  ). P-III 
SVMPs are mostly responsible for the hemorrhagic activ-
ity of venoms (  Gutiérrez et al, 2005  ) and, in the case of 
  A. picadoi  , it is likely that P-III SVMPs constitute major 
lethal factors and also toxins responsible for local myo-
toxicity, since this venom has a low content of myotoxic 
PLA  2  s (  Angulo et al, 2008  ); consequently, local myonecro-
sis is mostly secondary to the massive microvessel dam-
age, leading to ischemia induced by hemorrhagic SVMPs. 
Since P-III SVMPs are readily immunodepleted by poly-
valent antivenom, this explains the high efﬁ  cacy of this 
anti venom  to  neutralize the hemorrhagic, myotoxic and 
lethal effects of   A. picadoi   venom. In contrast, in the case of 
  A. mexicanus   venom, neutralization of hemorrhagic activity 
is highly efﬁ  cient whereas neutralization of lethality requires 
a higher volume of antivenom. Since P-III SVMPs comprise 
only 3.4 % of the venom of   A. mexicanus   (  Angulo et al, 
2008  ), it is suggested that the lethality of this venom by the 
intraperitoneal route is probably due to the action of PLA  2 s. 
This is in line with the relatively low toxicity of the venom, 
  i.e.  , high LD  50  , since myotoxic PLA  2  s from Central Ameri-
can viperid venoms are lethal only at relatively high doses 
(  Gutiérrez and Lomonte, 1995  ;   Gutiérrez and Lomonte, 
1997  ). Hence, the different proportions of P-III SVMPs and 
PLA  2  s in these venoms largely explain the variations in the 
neutralization of lethality. On the other hand, the neutraliza-
tion of the proteolytic activity on azocasein by the Costa 
Rican polyvalent antivenom is 31 and 12 times less effective 
than the neutralization of the hemorrhagic activity of the 
  Neutralization studies conﬁ  rmed the efﬁ  cacy of the poly-
valent antivenom to neutralize the toxic and the enzymatic 
activities of the two Atropoides venoms, albeit in the case of 
lethality induced by   A. mexicanus   venom, such neutraliza-
tion was achieved only when a challenge dose of up to 3 
LD  50  s was used. Our ﬁ  ndings agree with previous studies on 
the neutralization of   Atropoides   venoms by this polyspeciﬁ  c 
antivenom, although quantitative differences in the values 
of ED  50  s have been reported, probably evidencing varia-
tions between different batches of antivenom or intraspecies 
variability in the composition of venoms from various geo-
graphical origins (  Gutiérrez et al, 1985  ;   Rojas et al, 1987  ; 
  2001  ;   Gené et al, 1989  ;   Bogarín et al, 2000  ). As in the case 
of immunodepletion experiments, the ED  50   values for the 
neutralization of toxic and enzymatic activities of these 
heterologous venoms were similar to those for the neutra-
lization of   B. asper   venom, which is part of the immuniz-
ing mixture (  Saravia et al, 2001  ;   Gutiérrez et al, 2010  ; and   
Table 3  ). Moreover, in the case of neutralization of PLA  2  
activity, antivenom was more effective against heterolo-
gous   Atropoides   venoms than against homologous   B. asper  
venom (  Table 3  ). This further supports the concept that 
Activitya A. mexicanus A. picadoi
Lethality (LD50) 125μg4 2 μg
Hemorrhagic (MHD) 6μg 0.25μg
Myotoxic (MMD) 4.2μg 13µg
Coagulant (MCD) 15μg
No coagulation 
at 50μg
Proteolytic (units/mg) 150 145
Phospholipase A2 
(μEq/mg/min) 4.6 11.6
Table 2.  Toxic and enzymatic activities of the venoms of 
A. nummifer and A. picadoi.
aToxic activities are expressed as Median Lethal Dose (LD50), 
Minimum Hemorrhagic Dose (MHD), Minimum Myotoxic Dose 
(MMD) and Minimum Coagulant Dose (MCD) (See Materials and 
Methods for details).
Neutralization (ED50)a
Venom activity A. mexicanus A. picadoi Bothrops asperb
Lethality (4 LD50s) >2000µl/mg 353 (249-500) µl/mg 342 (224-465)
Lethality (3 LD50s) 891 (565-1404) µl/mg Not tested Not tested
Hemorrhagic 112 ± 27µl/mg 48 ± 38µl/mg 175 ± 37µl/mg
Myotoxic 1134 ± 275 380 ± 174 555 ± 159
Coagulant 972 ± 36µl/mg Venom devoid of coagulant effect 133 ± 8µl/mg
Proteolytic 1394 ± 44µl/mg 1481 ± 36µl/mg 942 ± 22µl/mg
Phospholipase A2 402 ± 16µl/mg 901 ± 69µl/mg 1268 ± 182µl/mg
Table 3. Neutralization of toxic and enzymatic activities of A. mexicanus and A. picadoi venoms by the polyvalent antivenom from 
Instituto Clodomiro Picado.
aNeutralization is expressed as the Effective Dose 50% (ED50) corresponding to the ratio µL antivenom/mg venom at which the effect 
of the challenge dose of venom was reduced to 50%. In the case of coagulant effect, neutralization is expressed as Effective Dose (ED), 
corresponding to the ratio µL antivenom/mg venom at which the clotting time of plasma is prolonged three times as compared with 
clotting time of plasma incubated with venom alone (see Materials and methods for details). In the case of lethality, the 95% conﬁ  dence 
limits are given in parentheses. For the other effects, results are presented as mean ± S.D. (n = 4).
bResults of neutralization of B. asper venom correspond to those described by Saravia et al (2001) using similar methodologies. In the 
case of proteolytic activity, ED50 was reported by Gutiérrez et al (2010).16
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con, 27, 841-848. 
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snake venoms by a polyvalent antivenom. Toxicon, 23, 887-893. 
  Gutiérrez JM, Rojas G, Lomonte B, Gené JA and Cerdas L. 1986. 
Comparative study of the edema-forming activity of Costa Rican 
snake venoms and its neutralization by a polyvalent antivenom. 
Comp Biochem Physiol C, 85, 171-175. 
  Gutiérrez JM, Lomonte B, Chaves F, Moreno E and Cerdas L. 
1986. Pharmacological activities of a toxic phospholipase A 
isolated from the venom of the snake   Bothrops asper  . Comp 
Biochem Physiol C, 84, 159-164. 
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28, 1127-1129. 
  Gutiérrez JM, Rojas G, Bogarín G and Lomonte B, 1996. 
Evaluation of the neutralizing ability of antivenoms for the treat-
ment of snake bite envenoming in Central America. In: Bon 
C. and Goyffon M (Eds)   Envenomings and Their Treatments  , 
Fondation Marcel Mérieux, Lyon, France, pp 223-231. 
  Gutiérrez JM and Lomonte B 1995. Phospholipase A  2   myotoxins 
from   Bothrops   snake venoms. Toxicon, 33, 1405-1424. 
  Gutiérrez JM and Lomonte B. 1997. Phospholipase A 2   myotoxins 
from   Bothrops   snake venoms. In: Kini RM (ed)   Venom Phos-
pholipase A  2  Enzymes .   Structure, Function and Mechanism  . 
Wiley, Chichester, United Kingdom pp. 321-352. 
  Gutiérrez JM, Rucavado A, Escalante T and Díaz C. 2005. Hemor-
rhage induced by snake venom metalloproteinases: Biochemical 
venoms of  A. picadoi  and  A. mexicanus , respectively, despite 
the fact that both effects are due to SVMPs, as judged by the 
ability of EDTA to abolish them. Such apparent discrep-
ancy is likely due to the fact that the hemorrhagic activity is 
largely due to P-III SVMPs whereas the proteolytic activity 
is mainly dependent on the action of P-I SVMPs, which in 
general have a higher enzymatic activity, albeit being less 
toxic, than P-III SVMPs (  Gutiérrez et al, 2009b  ). Since P-I 
SVMPs are immunodepleted to a lesser extent than P-III 
SVMPs by the antivenom, antivenomic and neutralization 
results clearly match regarding the neutralization of hemor-
rhagic and proteolytic effects.     
 CONCLUSIONS   
  ￿   Our observations demonstrate an extensive cross-
neutralization of   A. mexicanus   and   A. picadoi   venoms 
by the polyvalent antivenom used for the treatment of 
viperid envenomings in Central America.   
  ￿     Antivenomic observations evidenced that antivenoms 
readily immunodeplete P-III SVMPs from both ven-
oms, but immunodepletion of PLA  2  s, CRISPs and 
some P-I SVMPs and serine proteinases was achieved 
only to a partial extent, thus revealing the scarcity of 
(high-afﬁ  nity) antibodies against these proteins.   
  ￿   These  ﬁ  ndings, together with previous antivenomic 
studies, stress the need to search for immunization 
strategies aimed at enhancing the immune response 
against these poorly immunogenic venom toxins in 
order to increase the efﬁ  cacy and neutralizing potency 
of  antivenoms.       
ACKNOWLEDGEMENTS
  This study was supported by projects from the Vicerrec-
toría de Investigación, Universidad de Costa Rica (741-A7-
611), CRUSA-CSIC (2007CR0004), CONARE, and grants 
BFU2007-61563 and BFU2010-17373 from the Ministerio 
de Ciencia e Innovación, Madrid, Spain.
    STATEMENT  OF  COMPETING  INTERESTS 
  None  declared. 
    REFERENCES 
  Alape-Girón A, Sanz L, Escolano J et al. 2008. Snake venomics 
of the lancehead pitviper   Bothrops asper  : geographic, individual 
and ontogenetic variations. J Proteome Res 7, 3556-3571. 
  Angulo Y, Estrada R and Gutiérrez, JM. 1997. Clinical and labora-
tory alterations in horses during immunization with snake ven-
oms for the production of polyvalent (Crotalinae) antivenom. 
Toxicon, 35, 81-90. 
  Angulo Y, Escolano J, Lomonte B, Gutiérrez JM, Sanz L, 
Calvete JJ. 2008. Snake venomics of Central American pitvi-
pers. Clues for rationalizing the distinct envenomation proﬁ  les 
of   Atropoides  nummifer  and   Atropoides  picadoi . J Proteome 
Res, 7, 708-719. 
  Bogarín G, Morais JF, Yamaguchi IK et al. 2000. Neutralization 
of crotaline snake venoms form Central and South America by 
antivenoms produced in Brazil and Costa Rica. Toxicon, 38, 
1429-1441. 17
©The Authors | Journal of Venom Research | 2010 | Vol 1 | 8-17 | OPEN ACCESS
  Rojas E, Saravia P, Angulo Y et al. 2001. Venom of the crotaline 
snake   Atropoides nummifer   (jumping viper) from Guatemala 
and Honduras: comparative toxicological characterization, 
isolation of a myotoxic phospholipase A 2   homologue and 
neutralization by to antivenoms. Comp Biochem Physiol C, 129, 
151-162. 
  Saravia P, Rojas E, Escalante T et al. 2001. The venom of 
  Bothrops asper   from Guatemala: toxic activities and neutraliza-
tion by antivenoms. Toxicon, 39, 401-405. 
  Saravia P, Rojas E, Arce V et al. 2002. Geographic and ontogenic 
variability in the venom of the neotropical rattlesnake   Crotalus 
durissus  : pathophysiological and therapeutic implications. Rev 
Biol Trop, 50, 337-346. 
  Segura A, Castillo MC, Núñez V et al. 2010. Preclinical assess-
ment of the neutralizing capacity of antivenoms produced in six 
Latin American countries against medically-relevant  Bothrops  
snake venoms. Toxicon, in press. 
  Theakston RDG and Reid HA. 1983. Development of simple 
standard assay procedures for the characterization of snake ven-
oms. Bull World Health Org, 61, 949-956. 
  Theakston RDG. 1986. Characterization of venoms and standardi-
zation of antivenoms. In: Harris, JB (Ed)   Natural Toxins. Animal, 
Plant and Microbial  . Clarendon Press, Oxford, United Kingdom, 
pp 287-303. 
  Theakston RDG, Warrell DA and Grifﬁ  ths E. 2003. Report of a 
WHO workshop on the standardization and control of antiven-
oms. Toxicon, 41, 541-557. 
  Towbin H, Staehelin T and Gordon J. 1979. Electrophoretic trans-
fer of proteins from polyacrylamide gels to nitrocellulose sheets: 
procedure and some applications. Proc Natl Acad Sci USA, 76, 
4350-4354. 
  Valiente C, Moreno E, Sittenfeld A, Lomonte B and Gutiérrez JM, 
1992. An electrophoretic study on phospholipase A  2   isoenzymes 
in the venoms of Central American crotaline snakes. Toxicon, 30, 
815-823. 
  Wang WJ, Shih CH and Huang TF. 2004. A novel P-I class met-
alloproteinase with broad substrate-cleaving activity, agkislysin, 
from   Agkistrodon acutus   venom. Biochem Biophys Res Comm, 
324, 224-230. 
 World Health Organization. 1981.  Progress in the Characterization of 
Venoms and Standardization of Antivenoms.   World Health Organi-
zation, Geneva, Switzerland. WHO Offset Publication No. 58 
  World Health Organization. 2010.   Guidelines for the Production, 
Control and Regulation of Antivenom Immunoglobulins.   World 
Health  Organization,  Geneva,  Switzerland.      
and biophysical mechanisms involved in microvessel damage. 
Toxicon, 45, 997-1011. 
  Gutiérrez JM, Sanz L, Escolano J et al. 2008. Snake venomics of 
the Lesser Antillean pit vipers   Bothrops caribbaeus   and   Both-
rops lanceolatus  : correlation with toxicological activities and 
immunoreactivity of a heterologous antivenom. J Proteome Res, 
7, 4396-4408. 
  Gutiérrez JM, Lomonte B, León G et al. 2009a. Snake venomics 
and antivenomics: proteomic tools in the design and control of 
antivenoms for the treatment of snakebite envenoming. J Pro-
teomics, 72, 165-182. 
  Gutiérrez JM, Rucavado A and Escalante T. 2009b. Snake venom 
metalloproteinases. Biological roles and participation in the 
pathophysiology of envenomation. In: Mackessy SP (Ed)   Hand-
book of Venoms and Toxins of Reptiles  , CRC Press, Boca Raton, 
United States of America, pp 115-138. 
  Gutiérrez JM. 2009. Snakebite envenomation in Central Amer-
ica. In: Mackessy, S.P., Ed.,   Handbook of Venoms and Toxins of 
Reptiles  . CRC Press, Boca Raton, United States of America, 
pp. 491-507. 
  Gutiérrez JM, Sanz L, Flores-Díaz M et al. 2010. Impact of 
regional variation in  Bothrops  asper   snake venom on the design 
of antivenoms: integrating antivenomics and neutralization 
approaches. J Proteome Res, 9, 564-577. 
  Instituto Clodomiro Picado, 2008.   Determinación de Activi-
dades Tóxicas de Venenos de Serpientes y su Neutralización 
por Antivenenos. Manual de Métodos de Laboratorio.   Instituto 
Clodomiro Picado, San José, Costa Rica. 
  Lomonte B, Escolano J, Fernández J et al. 2008. Snake Venom-
ics and Antivenomics of the Arboreal Neotropical Pitvipers   
Bothriechis lateralis   and   Bothriechis schlegelii  . J Proteome Res, 
7, 2445-57. 
  Padlan EA, Silverton EW, Sheriff S, Cohen G, Smith-Gill SJ and 
Davies DR. 1989. Structure of an antibody-antigen complex: 
crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc 
Natl Acad Sci USA, 86, 5938-5942. 
  Rojas G, Jiménez JM and Gutiérrez JM. 1994. Caprylic acid 
fractionation of hyperimmune horse plasma: description of 
a simple procedure for antivenom production. Toxicon, 32, 
59-67. 
  Rojas G, Gutiérrez JM, Gené JA, Gómez M and Cerdas L. 1987. 
Neutralización de las actividades tóxicas y enzimáticas de 
cuatro venenos de serpientes de Guatemala y Honduras por el 
antiveneno polivalente producido en Costa Rica. Rev Biol Trop, 
35, 59-67. 